Amgen (AMGN) October volatility flat at 44 into FDA action
Amgen (Nasdaq: AMGN) : Amgen-AMGN $50.92. AMGN will present at the Goldman Sachs 30th Annual Global Healthcare Conference on June 10. AMGN is expected to provide an update on denosumab. AMGN's denosumab for treatment/prevention of postmenopausal osteoporosis and for bone loss in prostrate or breast cancer patients on hormone ablation therapy has a FDA action date of October 19. AMGN July option implied volatility is at 39, October is at 44; near its six month average of 42 according to Track Data, suggesting non-directional price movement. Paul Foster
You May Also Be Interested In
- Analyst Sees Affymax's (AFFY) Omontys as Comparable to Amgen's (AMGN) Epogen; Raises AFFY Target to $21
- SUPERVALU (SVU) Lower on Increased Volatility
- Brown Shoe (BWS) Volatility Dips as Shares Continue Higher
Create E-mail Alert Related Categories
OptionsRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
